Inactivation of APC is a strongly predisposing event in the development of colorectal cancer 1, 2 , prompting the search for vulnerabilities specific to cells that have lost APC function. Signalling through the mTOR pathway is known to be required for epithelial cell proliferation and tumour growth [3] [4] [5] , and the current paradigm suggests that a critical function of mTOR activity is to upregulate translational initiation through phosphorylation of 4EBP1 (refs 6, 7) . This model predicts that the mTOR inhibitor rapamycin, which does not efficiently inhibit 4EBP1 (ref. 8) , would be ineffective in limiting cancer progression in APC-deficient lesions. Here we show in mice that mTOR complex 1 (mTORC1) activity is absolutely required for the proliferation of Apc-deficient (but not wild-type) enterocytes, revealing an unexpected opportunity for therapeutic intervention. Although APC-deficient cells show the expected increases in protein synthesis, our study reveals that it is translation elongation, and not initiation, which is the rate-limiting component. Mechanistically, mTORC1mediated inhibition of eEF2 kinase is required for the proliferation of APC-deficient cells. Importantly, treatment of established APCdeficient adenomas with rapamycin (which can target eEF2 through the mTORC1-S6K-eEF2K axis) causes tumour cells to undergo growth arrest and differentiation. Taken together, our data suggest that inhibition of translation elongation using existing, clinically approved drugs, such as the rapalogs, would provide clear therapeutic benefit for patients at high risk of developing colorectal cancer.
The ability of the intestinal epithelium to regenerate after challenge has been well described [9] [10] [11] . We have shown that this is a Wnt-driven process that mimics the proliferation observed after Apc deletion 11, 12 and is a valuable model of the early stages of intestinal cancer. However, the underlying mechanisms controlling these processes are largely unknown. The serine/threonine kinase mTOR, particularly as part of mTORC1, is a known mediator of cell growth and proliferation 13 . Previous studies have suggested that mTORC1 may be important in both the intestinal stem-cell niche and for intestinal tumorigenesis 4, 5, 14 . We therefore queried the role of mTORC1 in intestinal proliferation after Wnt activation. Following Apc deletion there was an increase in the phosphorylation status of the mTORC1 effectors RPS6 and 4EBP1 that was dependent on MYC expression. Increased phosphorylation of these proteins was also seen during crypt regeneration ( Fig. 1a -c and Extended Data Fig. 1a ). Importantly, the mTOR inhibitor rapamycin blocked intestinal regeneration, demonstrating that mTOR signalling is required for this process (Fig. 1d, e ). Given that rapamycin did not affect apoptosis or proliferation in the normal intestine (Extended Data Fig. 1b , c), these data suggest that there may be a potential therapeutic window, between normal intestinal enterocytes and those with a high level of Wnt activity. Therefore, we deleted raptor (Rptor; an essential component of mTORC1) in *These authors contributed equally to this work. 1 Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK. 2 the intestinal epithelium (Extended Data Fig. 1d) . Surprisingly, normal gut homeostasis was unaffected by raptor loss 4 days after Cre induction, when using an epithelium-specific Cre-recombinase (VillinCre ER Rptor fl/fl ) (Extended Data Fig. 1e , f). Furthermore, 400 days after induction, no phosphorylation of RPS6 or 4EBP1 was observed, showing that Rptor deletion was sustained (Extended Data Fig. 2a ). Raptor loss caused no change in levels of either mitosis or apoptosis (Extended Data Fig. 2b , c) but proved to be essential for the proliferative phenotype observed during regeneration or after Apc deletion ( Fig. 1a, b , d-f). Nuclear localization of b-catenin and high levels of MYC could be demonstrated by immunohistochemistry (IHC), showing that Wnt activation is still present (Extended Data Fig. 3a, b) . Given that rapamycin treatment and Rptor deletion had similar effects, we examined whether rapamycin treatment was sufficient to modify intestinal tumorigenesis, either prophylactically or chemotherapeutically. First we assessed whether rapamycin could suppress a model of intestinal tumorigenesis, in which Apc deletion is targeted to Lgr5-positive stem cells using Lgr5Cre ER (Lgr5Cre ER Apc fl/fl ). Mice were treated starting 10 days after Cre induction and, in contrast to controls, remained tumour free for the duration of the experiment ( Fig. 2a, b ). Next we treated mice (Apc Min/1 or LGR5Cre ER Apc fl/fl ) with established adenomas. Remarkably, the mice lost their clinical symptoms of disease and survived significantly longer than controls (Fig. 2c, d and Extended Data Fig. 3c ). We next analysed the tumours from these mice over a time course after rapamycin treatment. Treatment caused a loss of proliferation specifically within the tumours by 72 h, and an increase in the number of lysozyme-positive Paneth cells ( Fig. 2e and Extended Data Fig. 3d, e ). By 30 days, most tumours had shrunk considerably to small non-proliferative lesions that no longer contained Paneth cells ( Fig. 2f and Extended Data Fig. 3f ). Within the normal intestine there are two main cell populations that show high levels of Wnt signalling; the label-retaining/progenitor population and the Paneth cell population 15 . Our data suggest that treatment of mice with rapamycin causes the differentiation of the tumour's Wnt-high progenitor cells into the other Wnt-high fate in the intestine: namely non-proliferative Paneth-like cells. The cell-cycle arrest in these cells was examined by staining for p21, p16 and p53. No increase in these markers was observed, suggesting that a classical cell-cycle arrest pathway had not been engaged (Extended Data Fig. 4a ). We reasoned that if mice were removed from rapamycin the tumours would regain proliferative capacity. Indeed, when rapamycin treatment was halted, signs of intestinal neoplasia were observed approximately 40-60 days later (Extended Data Fig. 3c ). This suggested that intestinal adenoma stem cells were still present. Tumours from Lgr5GFPCre ER mice were stained to detect LGR5-GFP positivity. We found that, after rapamycin treatment, numerous LGR5-positive cells were still present, indicating that, although rapamycin treatment causes a regression of the lesions, the tumour-initiating cells remain (Extended Data Fig. 4b ).
We next examined the mechanism of mTORC1 requirement after Apc loss. mTORC1 is known to regulate protein synthesis on multiple levels and most research has focused on two downstream effectors: 4EBP1 and S6K. A number of studies have suggested that translation initiation, via the 4EBP1-eIF4E axis, is the critical effector of mTOR in cancer 6, 16 . However, it has been shown that rapamycin preferentially inhibits the phosphorylation of S6K over 4EBP1 (ref. 8 ), suggesting that 4EBP1mediated inhibition of translation initiation may not be limiting in the context of Apc loss. To assess the changes in translational control in response to mTORC1 inhibition, we measured the polysomal distribution in wild-type, Apc-deficient and Apc/Rptor-deficient intestinal epithelial cells 4 days after gene deletion. Apc deletion resulted in a decrease in the number of polysomes, whereas Apc/Rptor co-deletion reversed this effect (Fig. 3a) . The decrease in the number of polysomes after Apc deletion could suggest either reduced translation initiation (and, consequently, a lower overall level of translation) and/or a faster rate of translational elongation. Global translation rates were measured using an in vitro intestinal crypt culture model 17 . The Apc-deficient cells were shown to have increased 35 S-labelled methionine/cysteine incorporation compared with wild type, showing higher overall levels of protein synthesis (Fig. 3b ). Unfortunately, Rptor deletion prevented the growth of crypts in vitro so this could not be assayed (Extended Data Fig. 5 ).
To measure the rate of translational elongation, an in vitro harringtonine run-off assay was performed 18 , as described in Methods. There was a .2.5-fold increase in ribosome run-off in crypts with Apc deletion compared with wild type (Fig. 3c and Extended Data Fig. 6a-d ). This suggests that, after Wnt activation, elongation, rather than initiation, is rate limiting for protein synthesis and that mTORC1 must be activated to overcome this.
Cycloheximide (an inhibitor of elongation 19 ) reduced proliferation associated with Apc deletion to a similar level to rapamycin (Extended Data Fig. 6e, f) . While cycloheximide is acknowledged to inhibit elongation 19 , it must be emphasized that 72 h treatment could result in broad alterations in protein synthesis. However, the Apc fl/fl -specific loss of proliferation observed here provides 'proof of principle' to demonstrate that the modulation of protein synthesis may be useful as a chemotherapeutic strategy.
As most previous work has suggested that translation initiation downstream of 4EBP1 is limiting to cancer 20 , it was important to probe known effectors of mTORC1 in this system. Given the alteration of elongation rates, eEF2K, a known target of S6K 21, 22 was of particular interest. eEF2K 
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is a negative regulator of eEF2, giving mTORC1 the ability to promote translational elongation via S6K (ref. 23 ). Using multiple mouse knockout and knock-in alleles, we further dissected the downstream effectors of mTORC1 in intestinal regeneration. S6k1/2 (also known as Rps6kb1 and Rps6kb2, respectively) knockout decreased intestinal regeneration, while knockout of Eif4ebp1/2 (coding 4EBP1 and 4EBP2, respectively) had no effect. As the 4EBP proteins are negative regulators of eIF4E, an increase (rather than a decrease) in regeneration may have been predicted, but this was not found. Moreover these intestines were still sensitive to rapamycin, demonstrating that rapamycin was acting via the mTORC1-S6K branch rather than the 4EBP1-eIF4E branch (Extended Data Fig. 7) . We then used an Eef2k-null mouse and showed that after irradiation and treatment with rapamycin, these mice were now resistant to mTORC1 inhibition, confirming the importance of translational elongation (Fig. 4a ). To ensure that S6K was not also acting through its more established effector, rpS6, we used an Rps6 phospho-mutant that cannot be phosphorylated by S6K. This was unable to phenocopy Rptor deletion (Fig. 4a) , showing that Wnt-driven regeneration requires increased translational elongation, mediated through mTORC1.
To prove that inhibition of eEF2K by S6K is required to allow increased eEF2 activity after Apc loss, we intercrossed VillinCre ER Apc fl/fl to Eef2k 2/2 mice and treated these with rapamycin. In contrast to VillinCre ER Apc fl/fl mice, these intestines were now resistant to the growth inhibitory effects of rapamycin (Fig. 4b, c) . Tellingly, these mice no longer show an increase in the inhibitory phosphorylation of eEF2 after rapamycin treatment (Extended Data Fig. 8 ).
To assess whether the increased elongation after Apc deletion had differential effects on cell-cycle-regulating proteins, RNA and protein levels of several key cell-cycle regulators were tested (Fig. 4d, e ). This analysis revealed that while there were increased RNA and protein levels of cyclin D1, cyclin D2, CDK4 and CDK6, cyclin D3 had increased protein levels in the absence of increased messenger RNA levels. Cyclin D3 protein levels were sensitive to rapamycin exposure, and this sensitivity depends on eEF2K (Extended Data Fig. 9 ). Additionally, ribosomes were shown to elongate approximately four times faster on cyclin D3 messages in Apcdeficient cells than in wild-type cells. No differences were detected in other messages tested (Extended Data Fig. 10 ). Taken together, these data suggest that cyclin D3 is translationally regulated at the level of elongation, consistent with previous reports 24, 25 . The contribution of cyclin D3 to the proliferative phenotype remains to be elucidated.
We report that mTORC1 is an essential downstream effector of Wnt signalling in the intestine. We show that intestinal proliferation associated with Wnt signalling requires the mTORC1-S6K-eEF2K-eEF2 axis, and that the resulting increase in the rate of elongation of specific polypeptides overcomes a limiting translational step. Our work highlights key functional roles for eEF2K and translational elongation in the control of the initiation of cancer and adenomatous proliferation. The 
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importance of elongation in this context has been suggested in a small number of publications, but this study provides key in vivo evidence [26] [27] [28] . Finally, we have also shown that targeting mTOR and translational control may be a viable strategy for chemoprevention of colorectal carcinoma in high-risk patients, and treatment of early stage disease. Indeed, recent studies have suggested that the chemopreventative agents aspirin and mesalazine also target mTOR 29, 30 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 

